Without knowing the material, size of nanoparticles and doses you are applying it is quite hard to give you a precise answer. Please tell us more.
In general the first thing I would check is thestate of aggregation of your nanoparticles in dispersion at the different doses you are applying. If they are by any chance aggregated when you apply them then the bioavailable dose would in fact be lower than your lower concentration dose.
HI Guillemotte, what are the volumes you are injecting and what liquid are the articles dispersed into? Are the oxide residues passivated on the surface or are they reactive? Have you ever thought of dispersing the particles in mouse plasma first so that once you inject them you already have a fully formed protein corona? please contact me in private if you would like to discuss more.
nanoparticles can be more translocated on lower doses than higher doses. This situation is due to aglomeration status of nanoparticles. If you use lower doses of nanoparticle, you can see more toxicological or tranlocation characters.